Ion Beam Applications SA

Welcome, everyone, to the IBA full year 2022 results conference call. At this time, all participants are in a listen-only mode. A question and answer session will follow the formal presentation. I would now like to turn the conference over to Olivier Legrain, CEO of IBA.

Good afternoon, everybody. Thank you for joining us on our full year results call. I'm Olivier, and with me today is our CFO Soumya. Before we start, I'd like to draw your attention to the company disclaimer on forward-looking statements. First of all, I'd like to start today by thanking the entire IBA team for their continued hard work over the course of this year. I am pleased to see that all that hard work is paying off. With a very strong year with growth across our business unit, and record order intake and backlog. As always, I will give an overview of our business and our progress over the course of 2022. Soumya will summarize our financial statements and then after I discuss the outlook and we will be very happy to take any questions. Now let's take a look at some of our key highlights for 2022. Here is a snapshot of the key 2022 financial highlights. As announced this morning, a few points to pick out here. Group revenue of 361.3 million, up 15% from 2021. The group rebate of 11.1 million and the net profit of 6.1 million. All-time record annual equipment order intake of 456 million and dosimetry order intake of 67 million euros. All-time record overall equipment and service backlog of 1.4 billion including equipment backlog of 713 million euros and service backlog of 669 million euros. finally our balance sheet continues to be extremely strong with 158 million euro gross and 117 million euro net cash at the end of the year providing us with significant stability and flexibility for the future period this slide will be familiar and cover the key objectives per business unit which includes growing market share, developing technologies for the future and delivering our backlog. Over the year, we have continued to deliver against these objectives. For dosimetry, order intake is up to a record €67 million and has been boosted by the acquisition of ScandiDOS and Modus. Within proton therapy, we have seen 17 new proton therapy rooms sold in 2022. Yes, ladies and gentlemen, 17 compared to 9 last year. Elsewhere, good progress has been made in terms of research collaborations, which we'll explore more later. Other accelerators sold 36 new systems compared to 31 in 2021. Here as well, once again, a record order intake. On the radiopharma side, the official launch of Pantera brings us a step closer to providing access to Actinium-225 to patients. And finally, within industrial, changing market dynamics in sterilization has brought increased demands, which here as well we'll discuss later. IBA remains committed to improving and investing in sustainability. This investment was across four streams in 2022, assessing the carbon footprint and lifecycle of our products, making changes across the entire organization to reduce carbon emission and waste, working with the organization to ensure IBA is an equitable and inclusive workplace, and finally, We have improved our B Corp score and, for the first time, linked one-third of our management performance payment with sustainability improvement. I will now pass to Soumya to talk us through the summary of the financials. Soumya.

Thank you, Olivier. On slide 10 here, you'll see a summary of the key figures for 2022. As Olivier mentioned, it's been a particularly strong year in terms of order intake and backlog across all of our businesses. We therefore achieved a rebate margin of 3.1% in 2022, which represents stop-line growth, but has been impacted by increasing OPEX and overhead investments for future growth and, of course, inflation during the year. Net result was €6.1 million. As a result of the strong performance, a dividend of €0.21 per share has been proposed, and that's an increase of around 10%. And I am pleased to report that we continue to have a solid net cash position of €117 million. I now hand you back to Olivier to take you through our business update.